Location · Dallas, TX
Clinical trials in Dallas, TX
724 recruiting studies have a site in the Dallas area, and 144 of them accept healthy volunteers. The area includes Fort Worth, Plano, Irving, Arlington, Garland, Richardson and nearby cities.
724 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
More recruiting studies (pay not posted)
- RecruitingPhase 3
ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
Atsena Therapeutics Inc.
- Location
- Phoenix, AZ + 13 other US sites
- Eligibility basics
- Ages 5+
- RecruitingPhase 3
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
- Location
- Huntsville, AL + 55 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
Biogen
- Location
- Huntsville, AL + 14 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
Regeneron Pharmaceuticals
- Location
- Phoenix, AZ + 12 other US sites
- Eligibility basics
- Ages 6 mo–6
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
Genentech, Inc.
- Location
- Beverly Hills, CA + 23 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
Nectero EAST System Clinical Study
Nectero Medical, Inc.
- Location
- Scottsdale, AZ + 35 other US sites
- Eligibility basics
- Ages 21–85
- RecruitingPhase 3
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
Octapharma
- Location
- Stanford, CA + 8 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Hoffmann-La Roche
- Location
- Dothan, AL + 58 other US sites
- Eligibility basics
- Ages 16–80
- RecruitingPhase 2
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Novartis Pharmaceuticals
- Location
- Birmingham, AL + 22 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
Azafaros B.V.
- Location
- Oakland, CA + 4 other US sites
- Eligibility basics
- Ages 4+
- RecruitingPhase 3
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Crystalys Therapeutics
- Location
- Birmingham, AL + 81 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
Crystalys Therapeutics
- Location
- Birmingham, AL + 82 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
Agios Pharmaceuticals, Inc.
- Location
- Indianapolis, IN + 2 other US sites
- Eligibility basics
- Ages 18–69
- Recruiting
Ambulatory Long Length URodynamics Evaluation
Bright Uro
- Location
- New Orleans, LA + 8 other US sites
- Eligibility basics
- Ages 22+
- RecruitingPhase 3
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
Agios Pharmaceuticals, Inc.
- Location
- Atlanta, GA + 3 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingPhase 3
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia
Agios Pharmaceuticals, Inc.
- Location
- Palo Alto, CA + 4 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingPhase 2
A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants
Crystalys Therapeutics
- Location
- Birmingham, AL + 40 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
Janssen Research & Development, LLC
- Location
- Garden Grove, CA + 7 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 3
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
ViiV Healthcare
- Location
- Phoenix, AZ + 36 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Bentonville, AR + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
Novo Nordisk A/S
- Location
- Anniston, AL + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT
Mercator MedSystems, Inc.
- Location
- Scottsdale, AZ + 17 other US sites
- Eligibility basics
- Ages 18–89
- RecruitingPhase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Intra-Cellular Therapies, Inc.
- Location
- Huntsville, AL + 19 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC
- Location
- Los Angeles, CA + 8 other US sites
- Eligibility basics
- Ages 2–17